CA Patent

CA2387013A1 — 6-position substituted indolinones, the preparation thereof and their use as pharmaceutical compositions

Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2001-04-19 · 25y expired

What this patent protects

The invention relates to a 6-substituted indoline of formula (I), wherein R1 to R5 and X are as defined in claim 1, isomers and salts of said compound, i n particular physiologically compatible salts of said compound having pharmacologically important characteristics, in particu…

USPTO Abstract

The invention relates to a 6-substituted indoline of formula (I), wherein R1 to R5 and X are as defined in claim 1, isomers and salts of said compound, i n particular physiologically compatible salts of said compound having pharmacologically important characteristics, in particular inhibiting action on different receptor-tyrosine kinases and cyclin/CDK complexes in addition to inhibiting the proliferation of endothelial cells and different tumor cells. The invention also relates to medicaments containing said compounds, the use of said compounds and a method for the production thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA2387013A1
Jurisdiction
CA
Classification
Expires
2001-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.